Davis Polk advised Morgan Stanley & Co. LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated, Wells Fargo Securities, LLC and RBC Capital Markets, LLC, as joint book-running managers of an SEC-registered follow-on offering by Integra LifeSciences Holdings Corporation of 4,025,000 shares of its common stock, which included 525,000 shares that the underwriters purchased pursuant to the exercise in full of their option to purchase additional shares. The net proceeds from the offering totaled approximately $152.4 million, which Integra intends to use for general corporate purposes, which may include reducing outstanding borrowings under Integra's senior credit facility and paying a portion of the purchase price for the proposed acquisition by Integra LifeSciences Corporation, Integra's wholly owned subsidiary, of Confluent Surgical, Inc., including its DuraSeal product line. 

Integra, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. 

The Davis Polk corporate team included partner Deanna L. Kirkpatrick, associate Derek Dostal and law clerk Rishab Kumar. The tax team included partner Samuel Dimon, associate Ethan R. Goldman and law clerk Christopher A. Baratta. Counsel Loyti Cheng and associate Kevin J. Klesh provided environmental advice. Associate Natalie A. Thomas provided intellectual property advice. Rosemarie Melendez was the legal assistant on the transaction. All members of the Davis Polk team are based in the New York office.